The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions.

This review looks at the connection between tuberous sclerosis complex (TSC) and autism. TSC is an inherited condition that causes non-cancerous tumors and often includes seizures and developmental delays. About 30-50% of people with TSC also have autism, though this can be hard to diagnose because both conditions share similar symptoms. The researchers suggest using team-based approaches for diagnosis and treatment, combining behavioral therapy, specific medications, and brain imaging.

This review examines the clinical relationship between tuberous sclerosis complex (TSC) and autism spectrum disorder (ASD). TSC is a hereditary disorder causing tumor growth in various organs, with manifestations including seizures, developmental delay, and skin abnormalities from TSC1/TSC2 gene mutations. The review emphasizes that 30-50% of TSC patients meet ASD clinical criteria, with ASD prevalence estimates ranging from 17-63% in TSC patients. Diagnosis is challenging due to shared symptoms like seizures and intellectual impairment.

The authors advocate for multidisciplinary approaches combining behavioral assessments, neuroimaging, and genetic testing, with personalized treatment plans including behavioral therapy, Everolimus (mTOR inhibitors), and advanced neuroimaging.

Clinicians should routinely screen for ASD in TSC patients given high co-occurrence rates. Multidisciplinary assessment teams are essential due to overlapping symptoms. Personalized treatment plans should integrate behavioral interventions, targeted medications like mTOR inhibitors, and advanced neuroimaging. Early diagnosis and individualized care planning are critical for optimal outcomes.

This is a literature review without original data collection or systematic methodology. Sample sizes and study quality of reviewed literature are not reported. The wide prevalence range (17-63%) suggests heterogeneity in diagnostic criteria across studies. No meta-analysis was conducted to synthesize findings quantitatively.

Tuberous sclerosis complex (TSC) is a hereditary disorder that leads to tumor growth in various organs. Manifestations from mutations in the TSC1 or TSC2 genes comprise seizures, developmental delay, and skin abnormalities. This literature search has been dedicated to emphasizing the critical role of early diagnosis and the formulation of individualized plans for this target population with co-occurring TSC and Autism Spectrum Disorder (ASD). Behavioral and developmental tests can evaluate ASD symptoms; neuroimaging methods like functional MRI and PET scans can identify brain abnormalities, and molecular genetic analysis can detect TSC1/TSC2 mutations.

Differential Diagnostic Approach These include medical histories and physical examinations to consider that ASD and TSC present the same symptoms. Although 90% of TSC patients are reported to have TSC-associated neuropsychiatric disorders, 30-50% of patients fulfil the clinical criteria of ASD. In comparison, the estimate for the rate of ASD prevalence in TSC patients ranges from 17 to 63%, with the characteristics of infantile spasms and early-onset epilepsy. The diagnosis is further challenged by the fact that there are shared symptoms between both, namely seizures and intellectual impairment.

The shared symptoms between TSC and ASD suggest the need for multidisciplinary approaches in both diagnosis and treatment. A personalized therapeutic plan should include behavioral therapy, medication with Everolimus, mammalian target of rapamycin (mTOR) inhibitors, and advanced neuroimaging. The future of research in biomarkers, molecular medicines, and improving diagnostic protocols holds great promise for optimizing patient care and treatment options.